Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma

Immunotherapy drugs are gaining popularity in the treatment of certain malignancies due to the success of these agents in recent clinical trials. Pembrolizumab is an immune checkpoint inhibitor that acts via binding to programmed cell death 1 (PD-1) receptors on T-cells, allowing for the constitutiv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Investig Med High Impact Case Rep
Autors principals: Kichloo, Asim, Albosta, Michael S., McMahon, Shane, Movsesian, Kimberly, Wani, Farah, Jamal, Shakeel M., Aljadah, Michael, Singh, Jagmeet
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448133/
https://ncbi.nlm.nih.gov/pubmed/32830561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709620951339
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars